Funding for this research was provided by:
Gabor Zellerman Chair in Nephrology Research
Article History
Received: 18 August 2021
Accepted: 16 September 2021
First Online: 18 October 2021
Declarations
:
: Dr. Reich is the national coordinating investigator and is a site investigator for the NEFIGARD study of Nefecon in IgAN (Calliditas). Dr. Reich is also the national coordinating investigator for the ALIGN study of Atrasentan in IgAN (Chinook). She is a site investigator and member of the academic steering committee for the ARTEMIS study of OMS721 in IgAN (Omeros), and a site co-investigator for the study of Cemdisiran in IgAN (Alnylam). She has received honoraria for consultation from Novartis, and Travere related to treatment of IgAN. The Toronto Glomerulonephritis Fellowship is supported by the Louise Fast Foundation. She has no other financial or non-financial conflicts to declare and the authors did not receive support from any organization for the submitted work. Dr. Gommerman and Dr. Haniuda have no conflicts of interest to declare.